Corporate presentation

Updated 15 July 2021 2

Forward looking statements

This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance.

Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases.

Camurus undertakes no obligation to update forward-looking statements 3

Long-acting medications addressing key healthcare challenges 4

Camurus snapshot

Rapidly growing commercial Broad late-stage pipeline stage company • +10 innovative clinical programs in , • Fully operational infrastructure in Europe pain, endocrine disorders and oncology and Australia • Three Phase 3 programs • Buvidal® to date available in 15 countries • Advancing early- and mid-stage candidates • Strong sales performance and growth

Market approvals Unique FluidCrystal® Partnerships Experienced Weekly and monthly nanotechnologies R&D collaborations, management & ® Buvidal for opioid • New generation long-acting licensing and royalty dedicated teams dependence depot technology arrangements with • Validated in +25 clinical trials pharmautical and and by approved products biotech companies

LISTED ON NASDAQ STO; TICKER CAMX MARKET CAP ~ SEK 11 billion EMPLOYEES: 140 HQ: Lund, Sweden REGIONAL OFFICES: Cambridge, Mannheim, Sydney 5

Leading FluidCrystal® extended-release technology

 Easy and convenient administration  Adopted to prefilled syringes and autoinjectors  Rapid onset & long-acting release  Manufacturing by standard processes  Applicable across substance classes  Strong intellectual property

Injection of liquid . formulation Encapsulating Slow release Drug release and conc using prefilled H2O liquid crystal gel of drug biodegradation of

syringe or triggered by blood gel matrix to full

autoinjector water uptake drug resolution time

Sources: Tiberg F, et al. Chapter in Long Acting Injections and Implants, Advances in Delivery Science and Technology 2012; Tiberg F, et al. OnDrugDelivery 2010; Tiberg F, et al. Drug Del. Sci. Tech., 21 (1) 101-109 2011. 6

FluidCrystal – Long-acting release

Immediate release pasireotide (Signifor®) Pasireotide FluidCrystal® (CAM4071)

10 10 Pasireotide IR 600 ug (SC Pasireotide FluidCrystal 20 thigh, n = 94) mg (SC thigh, n = 12)

1 1 pasireotide plasma concentration (ng/mL) concentration plasma pasireotide pasireotide plasma concentration (ng/mL) concentration plasma pasireotide 0,1 0,1 0 7 14 21 28 0 7 14 21 28 Time (days) Time (days) 7

Weekly and monthly depots

Population pharmacokinetic profiles for Buvidal vs sublingual buprenorphine

Weekly Buvidal vs. Daily sublingual buprenorphine Weekly vs. Monthly Buvidal

Population PK model analysis based on data from four clinical studies (N=236). Diagnostic testing demonstrated predictive buprenorphine concentrations and good agreement between observed and predicted data percentiles. Steady state data.

Sources: Abstract presented at the Annual conference of the Society for the Study of Addiction-November 2018; Albayaty M, Linden M, Olsson H, Johnsson M, Strandgarden K, Tiberg F. Adv Ther. 2017;34(2):560–575. 8

Recent business progress

•Strong commercial execution with Buvidal ‒ Expanding sales and commercial infrastructure ‒ Initiating diversification and prelaunch preparations for new products •Advancing pipeline ‒ Successful life-cycle management and new regulatory approvals ‒ Two ongoing Phase 3 studies of CAM2029 in acromegaly ‒ Phase 3 study of CAM2029 in neuroendocrine tumors (NET) starting ‒ Brixadi™ NDA filing accepted by FDA with PDUFA date 15 December 2021 ‒ Several early-stage clinical programs and partnerships advancing •Positive financial performance ‒ Strong revenue growth and improved financial results ‒ Solid cash position with no loans ‒ On track for profitability in 2022

1Total revenue SEK 680 – 750 million, whereof product sales SEK 620 – 680 million, and the operating result SEK -120 – 0 million excluding a USD 35 million milestone payment on approval of Brixadi™ in the US 9 Opioid dependence – worsened crisis during the pandemic

• Largest society burden of all drugs1 Escalating overdose deaths ‒ High need for better access to care and new during COVID-19 treatment alternatives ‒ Investment in treatment brings substantial value 12 Month-ending Provisional Number and saves lives of Drug Overdose Deaths in the US1 • New funding initiatives 100 000 90 000 All drugs ‒ President Biden recently issued a US$1.5 billion 80 000 initiative for substance use treatment and 70 000 2 Opioids prevention 60 000 ‒ Scottish Government initiative £250m investment 50 000 3 to tackle drug death crisis 40 000 30 000 Start lock-down • Significant limitations with current daily 20 000

medications the in US deaths of Number 10 000 ‒ Diversion, misuse, risk of overdose, poor retention, 0 burdens and stigma of daily buprenorphine and

methadone medications 12 month-ending period

1www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm; 10

Buvidal® – flexible long-acting treatment of opioid dependence

Weekly and monthly, subcutaneous buprenorphine for individualized treatment of opioid dependence within a framework of medical, social and psychological treatment in adults and adolescents 16 years or over1

Buvidal provides significant benefits to patients and society “Buvidal became ‒ Improved treatment outcomes and patient satisfaction1-3 my way out” ‒ Reduced treatment burden and improved quality of life2 4 Justin, Buvidal patient in ‒ Diminished diversion, misuse and pediatric exposure Australia ‒ Reduced treatment costs in the criminal justice system5

1Lofwall et al. JAMA Int. Med. 2018;178(6); 764-773; 2Frost et al, Addiction, 2019;114(8):1416-1426; 3Lintzeris N, et al., Results of the DEBUT Study, presented at CPDD Virtual Meeting June 22-24, 2020. 4EPAR; 5Dunlop A, et al. Introduction of Long-Acting Depot Buprenorphine in Prison - the UNLOC-T Study. Presented at CPDD Virtual Meeting June 22-24, 2020 11 Robust Buvidal sales growth continues under pressure by the pandemic

 Consistent double-digit quarter-by-quarter growth Product sales by quarter (MSEK) ‒ Exceptional uptake in Australia and the Nordics MSEK ‒ Progress in the UK, Germany, Spain and other markets 137 COVID-19 remains a barrier on many markets ‒ 32% 124 Average Q/Q  Buvidal market expansion continues growth rate 104 ‒ Available in 15 countries in Europe, Australia and MENA 94 ‒ P&R applications in new markets 76 ‒ 8 launches planned in 2021 49

 Successful life-cycle management and growing 30 scientific evidence 20 ‒ New approvals and important scientific publications Increasing media coverage ‒ Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2

2019 2020 2021

MENA; – Middle East and North Africa; P&R – price and reimbursement 12

Buvidal market expansion continues

Netherlands Switzerland  ~10,000 patients in opioid  10,000 patients1 dependence treatment1  Marketing approval received  Launch expected in Q3 2021  Launch expected in Q3 2021

France Croatia and Slovenia 1  >179,000 patients1  >8,000 patients  Positive HEOR assessment by  Preparing for launch Q3 2021 Haute Autorité de Santé  Preparing for launch in Q3 2021 Italy  ~70,000 patients1 Portugal  PMA ongoing  >17,000 patients1  Preparing for launch in Q3 2021 New Zealand  ~5,500 patients2,3 MENA Launch sequence  Market authorization received  Early access program in three countries Wave 1& 2 Wave 3 markets  PMA initiated  Several regulatory submissions Launched Wave 4 markets progressing

1EMCDDA 2020; 2Office of the Director of Mental Health and Addiction Services Annual Report 2018 and 2019; 3New Zealand Practice Guidelines for Opioid Substitution Treatment 2014 13 Increasing support for Buvidal and improved access to innovative ODT treatments

•Government initiatives to increase •Growing scientific evidence base funding and improve treatment access ‒ Positive results in peer-reviewed ‒ Scottish government and Public Health scientific journals England allocating funding for ODT and ‒ Affirmative “real world” outcome Buvidal1,2 studies ‒ Recommendation for significant investments ‒ Health-economical assessments in ODT and innovations in England3 demonstrating value of Buvidal to ‒ Processes ongoing in Germany and Sweden payors and society to improve HCP remuneration system •Increasing media attention •Adoption in the criminal justice system ‒ Unmet medical need and positive ‒ Expanding use of Buvidal with Australia, impact of ODT Germany and Scotland as forerunners ‒ Strong testimonials by patients ‒ Benefits of Buvidal clearly recognized, and HCPs including cost savings ‒ Buvidal identified as “game-changer” ‒ Estimated >100,000 people with opioid dependence in European prisons4

1https://www.gov.scot/publications/evaluation-opioid-substitution-treatment-scotlands-prisons-covid-19-contingency-patient-experience-follow-up-report/ 2Public health England "Additional drug treatment crime and harm reduction funding" 2021 3https://www.gov.uk/government/publications/review-of-drugs-phase-two-report/review-of-drugs-part-two-prevention-treatment-and-recovery; 4Bernuth, et al. Front. Psychiatry, 12 August 2020, and report “Prison and Drugs inn Europe – Current and future challenges” EMCDDA 2021 14 Growing scientific evidence base for Buvidal Important publications in 20211-3

Presentations at Scientific Conferences in 2021

2021 Q1 Q2 Q3 Q4

International ASAM CPDD ISAM AAAP Conferences 22-24 Apr 19-23 Jun 28 Sep – 1 Oct 9-12 Dec Virtual Virtual Valetta, Malta Naples, USA

European IOTOD Nord Op Sym EUROPAD ALBATROS 26-27 Apr 16-17 Sep 7-9 Dec 7-9 Dec Conferences Virtual Uppsala, SE Paris, FR Paris, FR

National IMIA21 Subst.-Forum RCPysch Kon. Suchtmed. ATHS Beroendemed. SSA Conf. SIPaD Conferences 26-28 Feb 8-9 May 21-24 Jun 1-3 Jul 19-22 Oct 23 Oct 4-5 Nov 10-12 Nov (selected) Virtual Virtual Virtual Munich, DE Biarritz, FR Sweden Virtual Rome, IT Schmerzkon. Schmerz+Palliativ-Tag Adictologia SESP DGS-Kon. SEPD 20-23 Oct 10-13 Mar 21 May 28-30 Oct 5-7 Nov 25-27 Nov Mannheim, Virtual Virtual Madrid, ES Berlin, DE Seville, ES DE SMMGP RCGP J Sociodrog Feder SerD APSAD Gefän.medizin 25-26 Mar 21-23 Oct 3-5 Nov 7-10 Nov 2-3 Dec Virtual Barcelona, ES Virtual Brisbane, AU Virtual

1Lintzeris, N. et al.; JAMA Netw Open 2021 May 3;4(5):e219041. 2Compton, Volkow, JAMA Netw Open. 2021 May 3;4(5):e219708.; 3Dunlop, A. et al, Addiction. Published 29 June 2021 15

Global strategy for Buvidal (Brixadi™)

REGION PARTNER NO OF PATIENTS ESTIMATED PEAK SALES

EU ~1.3 million €300 million2 Australia LAUNCH INITIATED IN 2019 HIGH-RISK OPIOID USERS1

North >2 million $600-1,200 million4, 5 America DIAGNOSED WITH OPIOID USE DISORDER IN THE US3

Middle East 5 & North >300,000 €25-75 million WITH OPIOID DEPENDENCE6 Africa EARLY ACCESS PROGRAMS INITIATED IN 2020

1European Drug Report 2019; 2Camurus estimate; 3SAMHSA, Results from the 2017 National Survey on Drug Use and Health, Sep. 2018; 4Opioid Use Disorder: Opportunity Analysis and Forecasts to 2027, GlobalData 2018; 5Camurus estimates; 6World Drug Report and NewBridge estimate 16

Significant opportunity in mid- to late-stage pipeline

Phase 1 Phase 2 Phase 3 Registration Market

CAM2043 CAM2029 CAM2029 Brixadi™ Buvidal® Pulmonary arterial Polycystic liver disease Acromegaly Opioid use disorder (US)1 Opioid dependence hypertension

CAM2047 CAM2032 CAM2029 episil® oral liquid -induced Prostate Neuroendocrine tumors Oral mucositis nausea and vomiting

CAM2048 CAM2043 CAM2038 Postoperative pain Raynaud’s phenomenon Chronic pain

Opioid dependence & Pain CAM4071 CAM4072 Endocrine disorders Genetic obesity disorders2 Rare diseases Oncology & Supportive care

1 Licensed to Braeburn 2 Licensed to Rhythm Pharmaceuticals worldwide 17 Buvidal (Brixadi) lifecycle management and geographic expansion

•New market approvals •Availability of Buvidal in MENA CAM2038 Chronic pain ‒ Buvidal 160mg monthly dose in the EU, ‒ Early access programs ongoing in ‒ Pre-submission meeting UK and Australia three countries held with EU Rapporteur ‒ Label expansion for Buvidal in Australia ‒ MAAs under review in four MENA ‒ Preparations ongoing for (harmonizing with the EU label) countries regulatory submission ‒ Further submissions planned in 2021 to EMA in H2 2021 •Brixadi™ in the US ‒ NDA for treatment of opioid use disorder resubmitted to then US FDA ‒ FDA accepted the FDA as a complete response ‒ New PDUFA date 15 December 2021 ‒ If approved, Brixadi will be available to US patients early 2022

CHMP - EMA Committee for Medicinal Products for Human Use; MENA – Middle East and North Africa; NDA – New Drug Application; PDUFA – Prescription Drug User Fee Act 18

CAM2029 – octreotide subcutaneous depot in Phase 3 development

•For the treatment of rare diseases; acromegaly, neuroendocrine tumors and polycystic liver disease. •Designed for enhanced efficacy and patient convenience 19 CAM2029 opportunity addresses key unmet medical needs in the SSA market

•Somatostatin analogues (SSAs) are •CAM2029 offers simplified dosing and US$ billion first-line medical therapy in acromegaly possibility of self-administration 2.8 and neuroendocrine tumors (NET) ‒ Ready-to-use prefilled syringe and pen CURRENT SSA device for enhanced convenience with option MARKET VALUE3 •But there are significant limitations with for self-administration current SSA treatments mUSD ‒ Difficult handling & administration CAM2029: SSA annual sales 3000 ‒ Sub-optimal exposure / treatment response 2500 Somatuline® Autogel® Sandostatin® LAR® 2000 1500 ® ® •Potential for improved biochemical, Sandostatin LAR (octreotide): 1000 symptom and tumor control 500 ‒ 500% higher bioavailability vs octreotide 0 LAR1 ‒ Well maintained or improved biochemical Somatuline® Autogel® (lanreotide): and symptom control indicated with CAM2029 in acromegaly and NET patients2

Source: 1Tiberg F, Br J Clin Pharmacol. 2015 Sep;80(3):460-72; 2.Pavel M et al, Cancer Chemotherapy and Pharmacology 2019; 83:375–385; 3 GlobalData 2020, excluding pasireotide sales 20

CAM2029 study program overview

Regulatory ACRO Phase 3 PC submission Four clinical ACRO trials completed Regulatory in healthy ACRO Phase 3 LTSE submission subjects and GEP-NET patients NET Phase 3 characterizing PK, PD and IND NET PLD Phase 2/3 Ext. treatment period safety (N=249) Ph. 3 Autoinj. PK

- 2020 2021 2022 2023 2024

ACRO Phase 3 PC ACRO Phase 3 LTSE NET Phase 3 PLD Phase 2/3 Autoinjector PK Randomized, double- Open-label, long-term Active controlled Phase 3 Placebo-controlled Phase PK bridging study of blind, placebo-controlled safety study in partial study in patients with 2/3 study in patients with prefilled syringe and study in SSA responders and full responders metastatic, well differen- polycystic liver disease autoinjector devices tiated GEP-NET (PLD)

Timelines are indicative. PK – pharmacokinetic; PD – pharmacodynamic; PC – Placebo control; LTSE – Long-term safety extension 21 Two ongoing pivotal Phase 3 studies of CAM2029 in acromegaly

•Efficacy trial •Long-term safety trial ‒ Phase 3, randomized, double-blind, placebo-controlled, ‒ Phase 3, open-label, single arm, multi-center trial to multi-center trial to assess efficacy and safety of CAM2029 assess the long-term safety and efficacy of CAM2029 ‒ ≥ 100 patients exposed to CAM2029 for 12 months ‒ 78 patients, full SSA responders • Roll-over patients from HS-18-633 and ‒ Regulatory requirements for efficacy data met • ‘New patients’ (partial SSA responders, irradiated patients, and full ‒ Primary endpoint: Proportion of patients with mean IGF-1 SSA responders) levels ≤ 1x upper limit of normal (ULN) at w22 and w24 ‒ Primary endpoint: Safety profile (adverse events) ‒ Study ongoing and recruiting ‒ Study ongoing and recruiting

HS-18-633 HS-19-647 Roll-over patients from efficacy study Possibility to CAM2029 once monthly N=70 Prior treatment roll-over to New patients with octreotide R long-term N=70 or lanreotide safety study Prior treatment CAM2029 once monthly N=78 Placebo with octreotide 2:1 Rescue with standard of care or lanreotide

4-8 weeks Week 1 Double-blind Week 24 4-8 weeks Week 1 Week 24 Week 52 screening treatment phase Endpoint assessment Screening Open label treatment phase 22

GEP-NET Phase 3 trial under start-up

 Phase 3, randomized, open-label, active-controlled multi-center trial to assess efficacy and safety of CAM2029 versus octreotide LAR or lanreotide ATG in patients with GEP-NET ‒ Approximately 300 patients with GEP-NET randomized 1:1 ‒ Primary endpoint: superiority of treatment with CAM2029 versus standard of care as determined by progression free survival in patients with GEP-NET ‒ Study initiated

•Patient population CAM2029 ‒ Adult patients with Option to switch to CAM2029 Survival histologically confirmed R (if primary endpoint met) follow-up advanced (unresectable Active comparator and/or metastatic) and well-differentiated NET of GEP origin Screening Week 1 Treatment period Endpoint Follow-up period assessment

* GEP – gastroenteropancreatic; NET – neuroendocrine tumors 23

CAM2029 update status

•Acromegaly •Prefilled pen development EstimatedCAM2029CAM2029 ‒ Two phase 3 studies ongoing ‒ Phase 1 bridging study ongoing peaksalessalespotentialpotential 1 ‒ Top-line results in 2022 ‒ Results in H2 2021 in thethe USUS and and EU5: EU5:1 ‒ Pre-launch activities initiated ‒ Validation for Phase 3 and commercial US$ 1.1-1.6 billion use ready in Q3 2021 ‒ Preparations for commercial Acromegaly2 Acromegaly2 manufacturing well under way ‒ Will be implemented in all clinical US$ 120-180 million programs US$ 120-180 million •Neuroendocrine tumors Neuroendocrine tumors3 Neuroendocrine tumors3 ‒ IND safe to proceed letter received US$ 720-1015 million from FDA for start of Phase 3 US$ 720-1015 million Polycystic liver disease4 ‒ Pivotal Phase 3 study initiated Polycystic liver disease4 US$ 265-415 million •Polycystic liver disease program US$ 265-415 million ‒ Type B meeting held with the FDA ‒ IND submitted to the FDA ‒ Phase 2/3 study planned to start H2 2021

1Globe Life Science market research. Data on file. 2Assuming CAM2029 autoinjector presentation and efficacy non-inferior to current long-acting SSA-products; 3Assuming CAM2029 autoinjector presentation and efficacy superior to current long-acting SSA-products; 4No currently available medical treatments 24

Strategies for continued value creation

Commercialization Innovation and pipeline Corporate development • Establish leadership in opioid • Advance our late-stage pipeline • Expand our commercial footprint dependence treatment in Europe, programs in neuroscience, • Deliver on key catalysts for robust, Australia and RoW endocrinology and oncology sustained growth • Support US launch of Brixadi • Continue invest in patient centric • Develop profitability through own • Initiate pre-launch activities in innovation and differentiated clinical sales, partnerships, business chronic pain and acromegaly programs development and M&A • Develop our leading FluidCrystal technology platform and partnerships Appendix

Camurus AB │ Ideon Science Park, SE-223 70 Lund, Sweden P +46 46 286 57 30 │ [email protected] │ camurus.com 26

Financials - second quarter and first half 2021

MSEK Apr – Jun Apr – Jun Change Jan – Jun Jan – Jun Change Jan – Dec 2021 2020 2021 2020 2020

Total revenues 138 81 +70% 264 130 103% 336

whereof product sales 137 76 +80% 261 124 110% 323

Operating expenses 179 102 +75% 315 219 44% 508

Operating result -60 -23 -156% -86 -100 14% -205

Result for the period -48 -20 +142% -70 -82 14% -167 Result per share, before and after dilution, SEK -0.89 -0.39 -130% -1.29 -1.58 +18% -3.18

Cash position 422 222 +90% 422 222 90% 462 27

Shareholders

Shareholders as of 30 June 2021 Number of shares % of capital % of votes Shareholder distribution Sandberg Development AB 22,000,692 40.3 40.3 Fjärde AP-fonden 3,330,676 6.1 6.1 Avanza Pension 2,506,313 4.6 4.6 Gladiator 1,762,953 3.2 3.2

Fredrik Tiberg, CEO 1,706,788 3.1 3.1 29.1%

Didner & Gerge Fonder 1,517,016 2.8 2.8 40,3% Svenskt Näringsliv 1,100,000 2.0 2.0 0,8% Lancelot Avalon 875,000 1.6 1.6 0,8% 0,9% Backahill Utveckling 826,491 1.5 1.5 1,0% State Street Bank and Trust 572,208 1.1 1.1 1,0% 1,1% Cancerfonden 550,000 1.0 1.0 1,5% 1,6% 6,1% 2,0% 4.6% Afa Försäkring 545,660 1.0 1.0 3,1% 2,8% 3,2% Camurus Lipid Research Foundation 505,250 0.9 0.9 CBNY Norges Bank 435,657 0.8 0.8 Carl-Olof and Jenz Hamrins Stiftelse 425,000 0.8 0.8 Other shareholders 15,878,867 29.2 29.2 In total 54,538,571 100.0 100.0 28

Experienced and committed management team

Fredrik Tiberg, PhD Education: M.Sc. in Chemical Engineering, PhD in Physical Eva Pinotti-Lindqvist Education: Bachelor’s of Science in Economics, Lund President & CEO, Head R&D Chemistry, Lund University Chief Financial Officer University In Company since: 2002 Previous experience: Professor in Physical Chemistry at In Company since: 2014 Previous experience: Chief Financial Officer at EQL Pharma, Holdings:1,706,788 shares, Lund University, Visiting Professor at Oxford University, Holdings:46,744 shares, Nordic Market Analyst at Nordic Drugs, Finance Consultant 90,000 warrants & 60,000 Institute for Surface Chemistry (Section head). 9,009 warrants and 33,750 at Poolia employee options employee options

Richard Jameson Education: B.Sc. in Applied Biological Sciences from Peter Hjelmström, MD, PhD Education: MD, PhD and Associate Professor from Chief Commercial Officer University West of England Chief Medical Officer Karolinska Institutet, Postdoctoral fellowship at Yale University In Company since: 2016 Previous experience: General Manager, UK & Nordics for In Company since: 2016 Previous experience: More than 15 years of experience Holdings:25,193 shares, Reckitt Benckiser (2010 – 2013) and Area Director Europe, Holdings: 22,500 employee Middle East and Africa for Indivior (2013 – 2016). options from the , including as Medical 58,000 warrants and 33,750 Director at Orexo and Head of Clinical Science at Sobi employee options

Fredrik Joabsson, PhD Education: M.Sc. in Chemistry, PhD in Physical Chemistry, Maria Lundqvist Education: B.Sc: in Business and Economics, Uppsala Chief Business Dev. Officer Lund University Head of Global HR University In Company since: 2001 Previous experience: More than 20 years of experience in In Company since: 2021 Previous experience: More than 20 years of experience of Holdings:49,170 shares , pharmaceutical R&D, business development and alliance Holdings: 22,500 employee leadership roles within Human Resources, including HR 15,000 subscription warrants management. options Director Nordics at Teva Pharmaceuticals and HR positions & 22,500 employee options at Tetra Pak, Vestas and AstraZeneca.

Annette Mattsson Education: Bachelor of Pharmacy, Uppsala University and Torsten Malmström, PhD Education: M.Sc. in Chemistry, PhD in Inorganic Chemistry, VP Regulatory Affairs Business Economics, Lund University Chief Technical Officer Lund University In Company since: 2017 Previous experience: More than 25 years of experience In Company since: 2013 Previous experience: More than 20 years of experience from Holdings:1,504 shares, within regulatory affairs, including European RA Holdings:46,858 shares & pharmaceutical R&D including Director Pharmaceutical 7,000 subscription warrants & Director/Global RA Lead at AstraZeneca and Global RA 22,500 employee options Development at Zealande Pharma, Director of Development 22,500 employee options Lead at LEO Pharma. at Polypeptide, Team Manager at AstraZeneca.

Andrew McLean Education: Bachelor of Laws (LL.B (Hons)), Aberystwyth Agneta Svedberg Education: M.Sc. In Radiophysics and B.Sc. In Medicine VP Corporate Development University and College of Law, Guildford (Law Finals) VP Clinical & Regulatory Dev. from Lund University, Executive MBA from Executive Foundation Lund & Senior Counsel Previous experience: General Counsel, Company Secretary In Company since: 2015 In Company since: 2021 & Chief Compliance Officer at Kyowa Kirin International, Holdings:16,087 shares, Previous experience: More than 25 years of experience in Holdings:22,500 employee International Business Lawyer at Recordati SpA, Head of 37,500 subscription warrants & drug development, incl. as COO at Zealand Pharma, CEO of options Legal Affairs at Shire Pharmaceuticals 22,500 employee options Cantargia, Senior VP Clinical Development at Genmab.